# Pembro/Carbo/Taxol in Endometrial Cancer

> **NCT02549209** · PHASE2 · COMPLETED · sponsor: **Daniela Matei, MD** · enrollment: 46 (actual)

## Conditions studied

- Endometrial Cancer
- Endometrial Adenocarcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02549209
- **Lead sponsor:** Daniela Matei, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-22
- **Primary completion:** 2019-12-12
- **Final completion:** 2022-02-10
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-03-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02549209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02549209, "Pembro/Carbo/Taxol in Endometrial Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02549209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*